Latest News and Press Releases

Ensovibep retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concernTesting on the full Omicron variant has initiated, with...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

Following the futility analysis, the independent Data and Safety Monitoring Board (DSMB) recommends that the recruitment of patients in the ensovibep arm of ACTIV-3 not continue in hospitalized...

Second immuno-oncology DARPin candidate to enter the clinic; combines immune stimulation with validated tumor-localizing technologyPreclinical data support potential to deliver tumor-localized immune...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

Ensovibep is shown in vitro to maintain inhibition against all variants of concern known to dateThe Company is also presenting a Trial in Progress poster on the EMPATHY clinical trial at the...

ZURICH-SCHLIEREN, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein...

-- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 ...

Global rights to registrational-stage ophthalmology drug return to Molecular PartnersImprovements in manufacturing and formulation have been made and tested in pre-clinical models with the potential...

Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the Delta variants of concern EMPATHY Phase 2/3 trial...